BioSante, Cell Genesys merge

LINCOLNSHIRE - BioSante Pharmaceuticals Inc. and South San Francisco-based Cell Genesys Inc. Wednesday completed their previously announced merger with BioSante as the surviving company. BioSante acquired all of the outstanding shares of Cell Genesys common stock. Effective Wednesday, trading in Cell Genesys common stock will be discontinued. The remaining nine workers at Cell Genesys also were terminated Wednesday. In an August federal filing, Cell Genesys had nine employees. BioSante said it intends to focus primarily on LibiGel, BioSante's testosterone gel in Phase III clinical development under a U.S. Food and Drug Administration-agreed Special Protocol Assessment for the treatment of female sexual dysfunction. BioSante also intends to seek future development opportunities for GVAX Immunotherapies including combinations with BioVant. In addition, BioSante owns 16 percent of Ceregene Inc., a former subsidiary of Cell Genesys.